A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer
Francesco Sclafani,Matteo Incarbone,Lorenza Rimassa,Nicola Personeni,Laura Giordano,Marco Alloisio,Armando Santoro +6 more
TL;DR: The presence of a single pulmonary metastasis was a favorable predictor of survival after complete pulmonary resection for metastatic colorectal cancer, and the other prognostic variables did not seem to affect survival and should not contraindicate such surgery in clinical practice.
Journal ArticleDOI
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations
Pasquale Persico,Elena Lorenzi,Agnese Losurdo,Angelo Dipasquale,A. Di Muzio,Pierina Navarria,Federico Pessina,Letterio S. Politi,G. Lombardi,Armando Santoro,Matteo Simonelli +10 more
TL;DR: The present review describes the physiopathological mechanisms by which IDH mutations lead to tumorigenesis, discussing their prognostic significance and pivotal role in the gliomas diagnostic classification system.
Journal ArticleDOI
Is High-Dose Chemotherapy After Primary Chemotherapy a Therapeutic Option for Patients With Primary Mediastinal Nonseminomatous Germ Cell Tumor?
Giuseppe Luigi Banna,Ugo De Giorgi,Benvenuto Ferrari,Luca Castagna,Marco Alloisio,Maurizio Marangolo,Giovanni Rosti,Armando Santoro +7 more
TL;DR: A single course of HDCT after induction chemotherapy appeared to be inapplicable in most of the authors' patients, mainly due to early progressive disease, and earlier HDCT administration followed by residual surgery should be considered for further investigation.
Journal ArticleDOI
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma
Lorenza Rimassa,Maria Reig,Giovanni Abbadessa,Markus Peck-Radosavljevic,William P. Harris,Vittorina Zagonel,Davide Pastorelli,Elena Rota Caremoli,Camillo Porta,Nevena Damjanov,Hitendra Patel,Bruno Daniele,Maria Lamar,Brian Schwartz,Terri Goldberg,Armando Santoro,Jordi Bruix +16 more
TL;DR: Tumor biopsies may help to reliably distinguish hepatocellular carcinoma from other tumors as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies.
Journal ArticleDOI
Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial
Carla Casulo,Armando Santoro,Kiyoshi Ando,Steven Le Gouill,Jia Ruan,John Radford,Luca Arcaini,Antonello Pinto,Reda Bouabdallah,Koji Izutsu,Simon Rule,Javier Munoz,Marie-Laure Casadebaig,Brian Fox,Nils Rettby,Justine Dell’Aringa,Richard Delarue,Kathryn Newhall,Myron S. Czuczman,Guillaume Cartron +19 more
TL;DR: The study consisted of 2 parts: dose finding (except for Arm D) to establish the recommended phase 2 dose (RP2D) for each combination and dose confirmation for bendamustine, and final subset analyses for pts with DLBCL and FL treated in Arms A, C, and D.